Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

被引：8
|
作者：
Duliege, Anne-Marie [1 ]
Arnold, Donald M. [2 ]
Boccia, Ralph [3 ]
Boxer, Michael [4 ]
Cooper, Nichola [5 ]
Hill, Quentin A. [6 ]
Liles, Darla K. [7 ]
Sholzberg, Michelle [8 ]
Zayed, Hany [1 ]
Tong, Sandra [1 ]
Bussel, James B. [9 ]
机构：
[1] Rigel Pharmaceut Inc, San Francisco, CA USA
[2] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Arizona Oncol, Tucson, AZ USA
[5] Imperial Coll NHS Trust, London, England
[6] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[7] East Carolina Univ, Vidant Med Ctr, Div Hematol Oncol, Greenville, NC 27858 USA
[8] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[9] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, New York, NY USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
736
引用
收藏
页数：3
相关论文
共 50 条
  • [21] SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, A THROMBOPOIETIN (TPO)-RECEPTOR-AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY
    Tarantino, Michael
    Bussel, James
    Geddis, Amy
    Guerrera, Michael
    Ikeda, Alan
    Nie, Kun
    Eisen, Melissa
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S46 - S46
  • [22] Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
    Raman, Subha V.
    Hor, Kan N.
    Mazur, Wojciech
    He, Xin
    Kissel, John T.
    Smart, Suzanne
    McCarthy, Beth
    Roble, Sharon L.
    Cripe, Linda H.
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [23] Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
    Subha V. Raman
    Kan N. Hor
    Wojciech Mazur
    Xin He
    John T. Kissel
    Suzanne Smart
    Beth McCarthy
    Sharon L. Roble
    Linda H. Cripe
    Orphanet Journal of Rare Diseases, 12
  • [24] Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
    Mark C. Genovese
    Maria W. Greenwald
    Sergio R. Gutierrez-Ureña
    Mario H. Cardiel
    Jeffrey E. Poiley
    Anna Zubrzycka-Sienkiewicz
    Christine E. Codding
    Annie Wang
    Weizhong He
    Rebecca Amos
    Raul Vinueza
    Xuegong Wang
    Jay P. Garg
    Alan J. Kivitz
    Rheumatology and Therapy, 2019, 6 : 503 - 520
  • [25] Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
    Genovese, Mark C.
    Greenwald, Maria W.
    Gutierrez-Urena, Sergio R.
    Cardiel, Mario H.
    Poiley, Jeffrey E.
    Zubrzycka-Sienkiewicz, Anna
    Codding, Christine E.
    Wang, Annie
    He, Weizhong
    Amos, Rebecca
    Vinueza, Raul
    Wang, Xuegong
    Garg, Jay P.
    Kivitz, Alan J.
    RHEUMATOLOGY AND THERAPY, 2019, 6 (04) : 503 - 520
  • [26] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Shirasugi, Yukari
    Ando, Kiyoshi
    Miyazaki, Koji
    Tomiyama, Yoshiaki
    Iwato, Koji
    Okamoto, Shinichiro
    Kurokawa, Mineo
    Kirito, Keita
    Hashino, Satoshi
    Ninomiya, Haruhiko
    Mori, Shinichiro
    Yonemura, Yuji
    Usuki, Kensuke
    Wei, Helen
    Lizambri, Richard
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (06) : 652 - 659
  • [27] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Yukari Shirasugi
    Kiyoshi Ando
    Koji Miyazaki
    Yoshiaki Tomiyama
    Koji Iwato
    Shinichiro Okamoto
    Mineo Kurokawa
    Keita Kirito
    Satoshi Hashino
    Haruhiko Ninomiya
    Shinichiro Mori
    Yuji Yonemura
    Kensuke Usuki
    Helen Wei
    Richard Lizambri
    International Journal of Hematology, 2012, 95 : 652 - 659
  • [28] Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
    Becker, Christian M.
    Johnson, Neil P.
    As-Sanie, Sawsan
    Ferreira, Juan C. Arjona
    Abrao, Mauricio S.
    Wilk, Krzysztof
    Imm, So Jung
    Mathur, Vandana
    Perry, Julie S.
    Wagman, Rachel B.
    Giudice, Linda C.
    HUMAN REPRODUCTION, 2024, : 526 - 537
  • [29] A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
    Riedl, M.
    Bernstein, J. A.
    Craig, T.
    Banerji, A.
    Magerl, M.
    Cicardi, M.
    Longhurst, H. J.
    Shennak, M.
    Yang, W.
    Schranz, J.
    Baptista, J.
    Busse, P.
    ALLERGY, 2017, 72 : 598 - 599
  • [30] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
    Burmester, Gerd
    Fiore, Stefano
    Hu, Chih-Chi
    Fay, Jonathan
    Lee, Eun-Bong
    Genovese, Mark
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 1035 - 1035
12345